Global Phase I clinical development for CSTONE PHARMA-B's (02616) core candidate CS5007, an EGFR/HER3 bispecific antibody-drug conjugate (ADC), has officially commenced after receiving approval from the Australian Human Research Ethics Committee (HREC).

This milestone signifies the full launch of CS5007's global clinical program and demonstrates the accelerating implementation of the company's Pipeline 2.0 strategy, with key follow-on assets entering a fast-paced clinical development track, which is expected to bolster confidence in its medium to long-term growth.

The company's CEO, Head of R&D, and Executive Director, Dr. Yang Jianxin, stated that the initiation of the global Phase I trial for CS5007 represents another significant achievement in the Pipeline 2.0 advancement.

This step further validates the innovative depth and global competitiveness of the company's proprietary ADC technology platform and clearly signals that its next-generation innovative pipeline is transitioning intensively from a technology incubation phase into a clinical realization phase, with subsequent assets gaining momentum and accelerating.

Amid short-term fluctuations in the capital markets, the company is steadily building a differentiated value moat based on its robust in-house R&D platform, a well-ordered pipeline portfolio, and a clear global strategy.

With its differentiated EGFR/HER3 dual-target design and solid preclinical data, CS5007 directly addresses two core challenges in treating advanced solid tumors: tumor resistance and tumor heterogeneity.

The company believes CS5007 has the potential to become a best-in-class innovative ADC product in this field.

Moving forward, the company will continue to be guided by clinical value, accelerating the global development of its innovative pipeline, committed to delivering transformative treatments for patients while creating long-term returns for investors.

The company's Chief Medical Officer, Dr. Shi Qingmei, noted that CS5007 is a highly representative and important asset within the company's oncology innovation Pipeline 2.0.

By simultaneously targeting the key EGFR and HER3 signaling pathways, CS5007 is expected to overcome the limitations of traditional single-target therapies, offering more comprehensive and sustained pathway inhibition, thereby achieving deeper and more durable anti-tumor activity across multiple solid tumor types.

It is worth highlighting that CS5007 utilizes a highly potent, clinically validated topoisomerase I inhibitor payload and exhibits a significant 'bystander effect,' which may further extend its therapeutic potential to tumors with varying levels of antigen expression.

The encouraging efficacy and safety profile observed in preclinical studies provide a solid scientific foundation for the upcoming clinical development.

With the formal initiation of the global Phase I first-in-human study, the company will systematically evaluate the safety, pharmacokinetic/pharmacodynamic (PK/PD) profile, and preliminary anti-tumor activity of CS5007 in patients with advanced solid tumors, providing precise data to inform subsequent development decisions.